Losartan
- Generic Name
- Losartan
- Brand Names
- Hyzaar, Cozaar
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN6O
- CAS Number
- 114798-26-4
- Unique Ingredient Identifier
- JMS50MPO89
- Background
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Los...
- Indication
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hyper...
- Associated Conditions
- Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
- Associated Therapies
- -
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Shyam S.D. Rao
- Target Recruit Count
- 24
- Registration Number
- NCT06211335
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)
- Conditions
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06150560
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Future University in Egypt
- Target Recruit Count
- 84
- Registration Number
- NCT06135493
- Locations
- 🇪🇬
Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University, Cairo, Egypt
Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 120
- Registration Number
- NCT06108063
- Locations
- 🇺🇸
The Steadman Clinic, Vail, Colorado, United States
GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-01-05
- Target Recruit Count
- 34
- Registration Number
- NCT05861336
- Locations
- 🇮🇹
UO Oncologia, AUSL della Romagna, Ravenna, Italy
🇮🇹U.O. Radioterapia IRCCS IRST, Meldola, Forlì, Italy
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 116
- Registration Number
- NCT05843162
Losartan and Memory
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 41
- Registration Number
- NCT05828940
- Locations
- 🇬🇧
Department of Psychiatry, University of Oxford, Oxford, United Kingdom
Azilsartan in Patients With Diabetic Kidney Disease and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 106
- Registration Number
- NCT05753696
- Locations
- 🇨🇳
the Second Afficiated Hospital, Zhejiang University, School of Medicine, Hanzhou, Zhejiang, China
Diabetic Autonomic Neuropathy and Left Ventricular Function
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- AHEPA University Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT05713396
- Locations
- 🇬🇷
Diabetes Center, 1st Propeudetic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, "AHEPA'' Hospital, Thessaloníki, Greece
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Valentina Puentmann
- Target Recruit Count
- 280
- Registration Number
- NCT05619653
- Locations
- 🇦🇹
University Medical Centre Vienna, Vienna, Austria
🇩🇪Institute for experimental and translational cardiovascular imaging, Frankfurt Am Main, Hessen, Germany
🇩🇪University Hospital Greifswald, Greifswald, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.